ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Thanks for the Info Yodle

I, as many on the board, believe Libigel is about to be partnered with Abbvie.

The Libigel Safety/Efficacy trial was halted prematurely in Sept 2012. while we were waiting for BPAX to announce the result of the study involving 3656 patients. They boxed up the trial data etc.. for future analysis. A condition of the merger with ANIP.

During this study they discovered accidentally that by restoring T-Levels to pre-menopausal levels. It reduced the risk of experiencing a cardiovascular event by at least 70%. This was never publicly disclosed other then in the patent applications.

According to the patent applications "cardiovascular events" means one of the following occurrences: a cardiovascular death, a non-fatal stroke, a non-fatal myocardial infarction, hospitalized unstable angina (including acute coronary syndrome), angioplasty, coronary bypass surgery, a pulmonary embolism and deep vein thrombosis.


The CEO told me that he would be looking for a larger pharmaceutical company to takeover and go through the regulatory process and any additional trials. He would be looking at a co-promotion deal. They are still prosecuting the patent, which I expect delayed acting on Libigel sooner.

In December 2015 additional claims were added which state that in addition to reducing cardiovascular events, restoring T-levels also reduces teh risk of Breast Cancer.

If you are interested in additional information, I will put together a series of links to previous posts that support these assertions.